[go: up one dir, main page]

MX2011008876A - Metabolitos analogos de ceramida. - Google Patents

Metabolitos analogos de ceramida.

Info

Publication number
MX2011008876A
MX2011008876A MX2011008876A MX2011008876A MX2011008876A MX 2011008876 A MX2011008876 A MX 2011008876A MX 2011008876 A MX2011008876 A MX 2011008876A MX 2011008876 A MX2011008876 A MX 2011008876A MX 2011008876 A MX2011008876 A MX 2011008876A
Authority
MX
Mexico
Prior art keywords
ceramide
relates
metabolites
analogous
analogous metabolites
Prior art date
Application number
MX2011008876A
Other languages
English (en)
Inventor
Markus Zollinger
Volker Brinkmann
Guido Jordine
Claudia Sayer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2011008876A publication Critical patent/MX2011008876A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invención se refiere a ciertos análogos de ceramida del FTY720 (2-amino-2-[2-(4-octilfenil)-etil]-propano-1,3-diol;fingoli mod). En particular, la presente invención se refiere a composiciones farmacéuticas que comprenden estos compuestos, así como a procesos para su preparación, y a su uso en el tratamiento de condiciones autoinmunes, tales como esclerosis múltiple.
MX2011008876A 2009-02-24 2010-02-23 Metabolitos analogos de ceramida. MX2011008876A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09153550 2009-02-24
PCT/EP2010/052231 WO2010097371A1 (en) 2009-02-24 2010-02-23 Ceramide-analogous metabolites

Publications (1)

Publication Number Publication Date
MX2011008876A true MX2011008876A (es) 2011-09-21

Family

ID=40447014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008876A MX2011008876A (es) 2009-02-24 2010-02-23 Metabolitos analogos de ceramida.

Country Status (14)

Country Link
US (1) US8673982B2 (es)
EP (1) EP2400960B1 (es)
JP (1) JP2012518671A (es)
KR (1) KR20110126631A (es)
CN (1) CN102333530A (es)
AU (1) AU2010217605B2 (es)
BR (1) BRPI1007994A2 (es)
CA (1) CA2752003A1 (es)
ES (1) ES2411138T3 (es)
MX (1) MX2011008876A (es)
PL (1) PL2400960T3 (es)
PT (1) PT2400960E (es)
RU (1) RU2011138963A (es)
WO (1) WO2010097371A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10391066B2 (en) * 2012-10-19 2019-08-27 Texas Tech University System Compositions and methods for the treatment of Parkinson's disease
US20150290099A1 (en) * 2012-11-30 2015-10-15 Amorepacific Corporation Novel pseudoceramide compound and production method for same
EP2964210B1 (en) * 2013-03-05 2023-10-04 Biocon Limited A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
KR101510683B1 (ko) * 2013-09-03 2015-04-10 (주)네오팜 카나비노이드 수용체에 길항작용을 가지는 신규한 유사 세라마이드 유도체 및 이를 포함하는 약학 또는 화장품 조성물
EP3118621A1 (en) 2015-07-14 2017-01-18 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126658T3 (es) * 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
JP3870419B2 (ja) * 1994-08-22 2007-01-17 三菱ウェルファーマ株式会社 ベンゼン化合物およびその医薬としての用途
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
ES2527055T3 (es) * 2004-07-30 2015-01-20 Novartis Ag Formulaciones de compuestos 2-amino-1,3-propanodiol
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
KR101346527B1 (ko) * 2005-12-15 2013-12-31 미쓰비시 타나베 파마 코퍼레이션 아민 화합물 및 그 의약 용도
CN101240002B (zh) * 2007-02-07 2011-01-26 首都医科大学 脂肪酰氨基酰阿糖胞苷缀合物、其制备方法和应用

Also Published As

Publication number Publication date
RU2011138963A (ru) 2013-04-10
BRPI1007994A2 (pt) 2018-03-13
EP2400960B1 (en) 2013-04-17
CA2752003A1 (en) 2010-09-02
PT2400960E (pt) 2013-06-28
KR20110126631A (ko) 2011-11-23
US20110306672A1 (en) 2011-12-15
CN102333530A (zh) 2012-01-25
AU2010217605A1 (en) 2011-08-18
ES2411138T3 (es) 2013-07-04
PL2400960T3 (pl) 2013-08-30
JP2012518671A (ja) 2012-08-16
EP2400960A1 (en) 2012-01-04
AU2010217605B2 (en) 2012-07-26
WO2010097371A1 (en) 2010-09-02
US8673982B2 (en) 2014-03-18

Similar Documents

Publication Publication Date Title
UA109661C2 (uk) Фармацевтична композиція співкристалів трамадолу і коксибів
WO2012056458A3 (en) Intermediate compounds and process for the preparation of fingolimod
IN2012DN01435A (es)
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
MX373763B (es) Uso de una composición de combinación de acamprosato y baclofeno de liberación sostenida, para el tratamiento de esclerosis lateral amiotrófica.
HRP20200249T1 (hr) Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol
EA017091B9 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
IN2012DN01434A (es)
IN2012DN02139A (es)
MX2011008876A (es) Metabolitos analogos de ceramida.
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
GEP20156231B (en) Agomelatine hydrochloride hydrate and preparation there of
PT3173400T (pt) Modificações cristalinas de (1r, 2r)-3-(3-dimetilamino-1- etil-2-metil-propil)-fenol
PH12013500371A1 (en) Therapeutic agent for pain
BR112013028607A2 (pt) composições sólidas contendo éter glicólico e água
CO6680629A2 (es) Compuestos con actividad antibacteriana contra clsotridium
MX2010009931A (es) Proceso para la preparacion de 2-amino-2-[2-(4-c3-c21-alquil-fenil )-etil]-propano-1,3-dioles.
SG143203A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
WO2013033602A3 (en) Fatty acid amides, compositions and methods of use
ECSP13013043A (es) Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma
MX2013013403A (es) Modificaciones cristalinas estables de cloruro de dotap.
IN2012DN06600A (es)
CO6361860A2 (es) (beta)-hidroxi-y-aminofosfonatos y metodos para la preparacion y uso de los mismos
TN2010000584A1 (en) Paediatric compositions for treating multiple scleoris
UA42862U (uk) ЗАСТОСУВАННЯ М'ЯКОЇ ЛІКАРСЬКОЇ ФОРМИ, ЯКА МІСТИТЬ АКТИВНУ РЕЧОВИНУ β-ФЕНІЛЕТИЛАМІД 2-ОКСИСУКЦИНАНІЛОВОЇ КИСЛОТИ, ДЛЯ ЛІКУВАННЯ ОПІКОВИХ УРАЖЕНЬ ШКІРИ

Legal Events

Date Code Title Description
FA Abandonment or withdrawal